Antibiotice S.A.

BVB:ATB Stock Report

Market Cap: RON 1.2b

Antibiotice Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Ioan Nani

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure17.3yrs
CEO ownershipn/a
Management average tenure5yrs
Board average tenure1yr

Recent management updates

Recent updates

Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last Year

Apr 25
Antibiotice (BVB:ATB) Is Paying Out Less In Dividends Than Last Year

Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Apr 04
Antibiotice (BVB:ATB) Will Pay A Smaller Dividend Than Last Year

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 23
Is Antibiotice (BVB:ATB) Using Too Much Debt?

Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Jun 07
Market Might Still Lack Some Conviction On Antibiotice S.A. (BVB:ATB) Even After 25% Share Price Boost

Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

Jan 30
Antibiotice S.A. (BVB:ATB) Looks Just Right With A 26% Price Jump

We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

Jan 13
We Think Antibiotice (BVB:ATB) Can Manage Its Debt With Ease

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Aug 16
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Safely

Is Antibiotice (BVB:ATB) A Risky Investment?

Jun 08
Is Antibiotice (BVB:ATB) A Risky Investment?

These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Mar 10
These 4 Measures Indicate That Antibiotice (BVB:ATB) Is Using Debt Extensively

Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Feb 11
Tread With Caution Around Antibiotice S.A.'s (BVB:ATB) 5.8% Dividend Yield

Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Jan 12
Calculating The Intrinsic Value Of Antibiotice S.A. (BVB:ATB)

Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Dec 16
Are Antibiotice's (BVB:ATB) Statutory Earnings A Good Guide To Its Underlying Profitability?

Is Antibiotice (BVB:ATB) Using Too Much Debt?

Nov 24
Is Antibiotice (BVB:ATB) Using Too Much Debt?

CEO

Ioan Nani (66 yo)

17.3yrs
Tenure

Mr. Ioan Nani is the CEO and Non-Independent Director at Antibiotice S.A. since 2009. Mr. Nani served as General Manager, General Director and had been its Chairman since April 15, 2025 until June 2025 and...

Leadership Team

NamePositionTenureCompensationOwnership
Ioan Nani
CEO & Director17.3yrsno datano data
Paula-Luminita Coman
Executive Director of Financial & CFOno datano datano data
Eugen Osadet
Engineering & Investment Director26.3yrsno datano data
Cornelia Moraru
Investors Relation Officer and Executive Director of Technical & Production3.3yrsno datano data
Liviu Vatavu
Executive Director of Legal & Corporate Governance6.3yrsno datano data
Ovidiu Bataga
Executive Director of National Salesno datano datano data
Mihaela Murariu
Executive Director of Human Resource3.6yrsno datano data
Stefania Alexandru
Deputy General Managerless than a yearno datano data
5.0yrs
Average Tenure
55.5yo
Average Age

Experienced Management: ATB's management team is considered experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ioan Nani
CEO & Director17.3yrsno datano data
Ionut-Sebastian Iavor
President of the Board2.3yrsno datano data
Catalin Lungu
Independent Director2.3yrsno datano data
Laura Cristina Bogdan
Non-Independent Board Member1yrno datano data
Andrei Novac
Independent Board Member1yrno datano data
Corina Vulpes
Independent Board Member1yrno datano data
Madalina-Anca Bonifate
Independent Directorless than a yearno datano data
1.0yrs
Average Tenure
49yo
Average Age

Experienced Board: ATB's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/22 02:14
End of Day Share Price 2026/04/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Antibiotice S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vladimira UrbankovaErste Group Bank AG
Alex DodoiSSIF BRK Financial Group S.A.